Mayne Pharma Group (OTCMKTS:MAYNF – Get Free Report) is expected to announce its resultson Thursday, August 27th. Analysts expect Mayne Pharma Group to post earnings of ($0.2359) per share and revenue of $115.3910 million for the quarter.
Mayne Pharma Group Price Performance
Mayne Pharma Group stock opened at $2.30 on Wednesday. Mayne Pharma Group has a one year low of $1.40 and a one year high of $4.00. The business has a fifty day moving average of $1.98 and a two-hundred day moving average of $1.81.
Mayne Pharma Group Company Profile
Mayne Pharma Group (OTCMKTS:MAYNF) is a specialty pharmaceutical company focused on the development, manufacturing and commercialization of prescription products. The company’s portfolio spans oral, transdermal and topical dosage forms, with a particular emphasis on women’s health, dermatology, pain management and other niche therapeutic areas. Through both branded and generic offerings, Mayne Pharma seeks to address unmet patient needs and provide cost-effective alternatives to established treatments.
In its development operations, Mayne Pharma leverages a combination of in-house research and external partnerships to advance product candidates through regulatory review.
Read More
- Five stocks we like better than Mayne Pharma Group
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Receive News & Ratings for Mayne Pharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mayne Pharma Group and related companies with MarketBeat.com's FREE daily email newsletter.
